UNSPSC 51171623: Phenolphthalein

This classification denotes an organic carcinogen with the molecular formula C20H14O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6QK969R2IF, chemically known as 3,3-bis(p-hydroxyphenyl)phthalide but generally known as phenolphthalein, which bears US NIH Compound Identifier 4764. European Medicines Agency schedules Phenolphthalein in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09773MIG.

UNSPSC 51171623 Phenolphthalein is a Commodity code under which state and local governments procure phenolphthalein and related chemical reagents for specimen testing, drug screening, and pharmaceutical applications. Recent solicitations show procurement bodies buying phenolphthalein primarily as a component reagent in offender drug testing protocols, in multi-source pharmaceutical cooperative arrangements, and in exploratory pharmacy benefit initiatives. The issuing bodies mix county departments, state health agencies, and multistate cooperative purchasing alliances — notably Collin County Community Supervision and Corrections Department in Texas, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon. Drug testing and specimen collection under this code involves immunoassay screening platforms that depend on reagents like phenolphthalein as part of comprehensive LC/MS/MS or GC/MS confirmation workflows.

Recent activity concentrates in Texas and Minnesota. Collin County's RFP 2026-327 for offender specimen collection and drug testing services, due July 23, 2026, encompasses approximately 25,031 annual tests across five-panel and six-panel immunoassay screening with estimated annual contract value of $600,000 and a two-year term commencing September 1, 2026, with three optional one-year renewals. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other member states, with awarded vendors effective July 1, 2026 and a two-year initial term. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 seeking market intelligence on direct-to-manufacturer prescription programs, indicating exploratory state-level interest in pharmacy benefit restructuring that may generate downstream reagent and pharmaceutical demand.